Home > Oncology > BCC 2019 > St. Gallen Consensus > St. Gallen Consensus – Adjuvant Chemotherapy after Neoadjuvant Chemotherapy? Going Beyond EMA/FDA

St. Gallen Consensus – Adjuvant Chemotherapy after Neoadjuvant Chemotherapy? Going Beyond EMA/FDA

Conference
BCC 2019
Trial
KATHERINE, CREATE-X

At the time of the St. Gallen Conference 2017, there was still a lack of scientific data to decide for which patients adjuvant systemic therapy should be recommended after neoadjuvant systemic therapy. However, recently, the results of the CREATE-X trial [1] and the KATHERINE trial [2] have been published. In patients with a Her2-negative tumour who had residual disease after neoadjuvant chemotherapy, the CREATE-X trial showed a clinical benefit (e.g. a reduction in recurrence and longer overall survival) of adjuvant treatment with capecitabine. In the KATHERINE trial, patients with a Her2-positive tumour who had residual disease after Her2-targeted neoadjuvant therapy had more clinical benefit from adjuvant treatment with TDM-1 compared to adjuvant treatment with trastuzumab. In line with these data, 83% of the panellists endorsed adjuvant treatment with capecitabine in patients with triple-negative breast cancer and residual disease (>1 cm residual tumour in the breast and/o...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on